Keyword: Johnson & Johnson
J&J could suffer a big patent loss for Zytiga, but even if that happens, the company argues it can grow faster than its peers.
The FDA approved Xarelto for chronic coronary or peripheral artery disease, an indication analysts said is worth $1.5 billion.
In a new report, Leerink Partners analyst Geoffrey Porges detailed which "signature" drugs might struggle to grow due to U.S. pricing pressure.
Several big drugmakers have posted big share price gains in the first nine months of the year, while other companies have seen only modest declines.
Johnson & Johnson taps social, digital and PR to shine a spotlight on vision care in a new worldwide J&J Vision campaign.
The number of open innovation challenges in pharma grows by the day. But what’s driving them? That’s what Luminary Labs wanted to know.
Tasuku Honjo wins Nobel Prize for PD-1 research; Legend fires back at CAR-T data fabrication allegation; Takeda alumni demand more on Shire buyout.
Two talcum cases have ended in mistrials in recent weeks as juries failed to determine whether marketer J&J is responsible for plaintiffs' cancers.
In its latest development deal, the outbreak readiness group CEPI has awarded J&J and Oxford University $14.6 million for work on a MERS vaccine.
Pharma companies Pfizer, Merck and Johnson & Johnson are dodging billions of dollars of tax payments annually, an Oxfam report concluded.
